Figure 1From: A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma Patient flowchart for patients assessed as having unresectable disease (panel 1A, n = 14), and for those assessed as having borderline resectable disease (panel 1B). Back to article page